Forever Chemicals, Borrowed Hormones — How Endocrine Disruptors Rewrite the Body's Messages

The endocrine system runs on a simple principle: molecules in vanishingly small concentrations carry instructions across the body. A pulse of estrogen tells uterine tissue to thicken. A surge of cortisol prepares muscles and liver for stress. A trickle of thyroid hormone, calibrated within tight bounds, sets metabolic rate for every cell. Hormones are messages, and the cells that receive them are exquisitely tuned to recognize specific molecular shapes. This sensitivity is the system's strength. It is also its vulnerability.

An endocrine disruptor is any chemical from outside the body that interferes with this signaling — usually by mimicking a hormone closely enough to bind its receptor, or by blocking the receptor so the real hormone cannot. The list of suspects has grown long. Bisphenol A (BPA), used in plastics and the linings of canned goods, mimics estrogen. Phthalates, the plasticizers that make vinyl flexible and fragrances stick, interfere with testosterone signaling. Per- and polyfluoroalkyl substances (PFAS) — the "forever chemicals" used in nonstick coatings, waterproof fabrics, and firefighting foam — disrupt thyroid function and metabolic regulation. Parabens, used as preservatives in cosmetics and pharmaceuticals, bind weakly to estrogen receptors. Atrazine, one of the most widely used herbicides in American agriculture, alters sex differentiation in amphibians and is suspected of doing similar work in mammals.

What makes these chemicals difficult to regulate is that they violate one of toxicology's foundational assumptions: that the dose makes the poison. For most toxic substances, higher exposure produces proportionally greater harm, and a sufficiently low dose is effectively safe. Endocrine disruptors often do not follow this rule. Because hormones operate at concentrations measured in parts per billion or trillion, the body's machinery is built to respond to tiny signals — and a tiny dose of a hormone mimic can produce a substantial biological effect. Some disruptors show non-monotonic dose-response curves, where low doses produce effects that disappear or reverse at higher doses, a pattern that confounds standard regulatory testing built around finding a maximum safe exposure level.

The exposures most consequential are not typically the dramatic ones. They are chronic, low-level, and prenatal. Developmental windows — fetal life, infancy, puberty — are periods when hormonal signaling literally builds the body, sculpting reproductive anatomy, brain organization, immune calibration, and metabolic set points. A disruption during these windows is not the same as a disruption in adulthood. It is a corrupted instruction in the blueprint, and the consequences play out over a lifetime. The evidence base now connects prenatal phthalate exposure to altered male reproductive development, prenatal BPA exposure to behavioral changes in children, PFAS exposure to thyroid disorders and elevated cholesterol, and chronic low-dose exposure across multiple disruptor classes to metabolic dysfunction, including obesity and type 2 diabetes — sometimes referred to in the literature as the "obesogen" hypothesis.

This thread continues directly from the microplastics work this blog explored earlier.

Microplastics are not just physical particles. They are carriers — for BPA, for phthalates, for the additives used in their own manufacture, and for ambient pollutants that adsorb to plastic surfaces in the environment. When microplastics enter the bloodstream and tissues, they bring their chemistry with them. The cellular damage explored in earlier posts is one consequence; the hormonal damage explored here is another. The two are not separate stories. They are the same story told from different angles.

The regulatory landscape has lagged the science, and the reasons are structural. Endocrine disruptors are economically embedded. Phthalates and BPA are foundational to modern packaging and consumer goods. PFAS are in firefighting foam, semiconductor manufacturing, medical devices, and outdoor gear — industries that have, in many cases, fought hard against restriction. The European Union has moved faster than the United States on most fronts, banning specific phthalates from children's products and pursuing broader PFAS restrictions, while U.S. action has come piecemeal, often through state-level legislation in California, Maine, and elsewhere. The chemistry industry's standard response — that any specific disruptor is "safe at current exposure levels" — sidesteps the harder question, which is what happens when the body is exposed to dozens of disruptors simultaneously, in combinations that have never been tested.

There is a recurring asymmetry in environmental health: the substances are cheap to produce, profitable to sell, and expensive to remove from the body, the water table, and the bloodstream once they are there. PFAS earned the name "forever chemicals" because their carbon-fluorine bonds resist nearly every form of environmental degradation. They persist. They bioaccumulate. They show up in the blood of nearly every American tested, and in arctic wildlife thousands of miles from any source. What we have done, collectively, is run an uncontrolled experiment on the endocrine systems of every living person, with results we will be reading for the rest of the century. Understanding this — at the level of cells, hormones, and policy — is part of what biopsychology in an industrialized world has to mean.